AI Software for same-day dementia evaluation

Using EEG visuospatial deficits to estimate clinical endpoints of dementia

Add us to your clinic today!

Reduce inconclusive test results with efficient dementia evaluation

Vistim Labs’ high-resolution biomarkers correlate with traditional PET, CSF, brain atrophy & cognitive endpoints.

Learn more about our scientific approach, and…

Collaborate with us Today

Vision

We see a new standard of care where patients, clinicians, and researchers can quickly and easily perform dementia evaluation in-office, enabling opportunities to intervene to save individuals, families, and communities.

Mission

To increase patient access to care and to empower clinical decision making ability with our dementia evaluation tools. Our AI estimates clinical endpoints of neurodegeneration by identifying visuospatial & cognitive deficits from stimulated EEG patterns that indicate specific levels of amyloid and tau protein accumulation as well as cognitive impairment.

Learn more about our approach

Dementia Evaluation by Visuospatial Deficits

Visuospatial deficits occur when areas of the brain responsible for human perception are damaged by disease, such as Alzheimer’s, Parkison’s, and Lewy Body Disease. These deficits are characterized by a person’s reduced ability to understand their environment and cause downstream handicaps to normal cognitive function. As a result, visuospatial deficits are known to affect many aspects of daily life, such as navigation, reading, dressing, and recognizing faces.

Measuring visuospatial deficits is an effective way to perform dementia evaluations since they are common in people with dementia and other neurological disorders including Schizophrenia and Traumatic Brain Injuries. They can also be an early sign of cognitive decline and neurodegeneration.

Vistim Labs’ AI software provides dementia evaluation using visuospatial deficits measured via EEG to estimate clinical endpoints of dementia. Our dementia evaluation software compares these deficits across our known patient database and accurately estimates endpoints such as: presence of amyloid and tau protein in the brain, brain volume atrophy (e.g. CT and MRI), and patient performance in psychological testing (e.g. MMSE, CERAD, and TASIT). Additionally, our dementia evaluation is 100% reimbursable, non-invasive, portable, affordable, and easy to use.

For these reasons, researchers and clinicians rely on Vistim Labs biomarkers for dementia evaluation: to identify, treat, and monitor people with dementia and other neurological disorders.